Actos
Actos is a pharmaceutical drug with 7 clinical trials. Currently 1 active trials ongoing. Historical success rate of 83.3%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
6
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
83.3%
5 of 6 finished
16.7%
1 ended early
1
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
Prevention of Progression of Prediabetes, Obesity and CV Risk
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.
Clinical Trials (7)
Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
Prevention of Progression of Prediabetes, Obesity and CV Risk
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.
A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7